NewHydrogen's $3 Million Lifeline: What the GHS Deal Actually Means

NewHydrogen, a penny stock that develops hydrogen-production technology, announced this week it had secured an equity financing agreement with GHS Investments for up to $3 million. Headlines call it a win. The numbers behind the deal tell a different story — one about a company with zero revenue, under $1 million in assets, and a runway measured in quarters, not years.

Before getting to the deal terms, it helps to understand the position the company is in.

Where NewHydrogen actually stands

As of June 30, 2026, NewHydrogen reported $739,528 in cash and $809,282 in total assets. That is not a balance sheet that can sustain a multi-year research program. The company generates no revenue. None. It has never generated meaningful revenue, and its accumulated deficit since inception stands at $180 million.

For the second quarter alone, it reported a net loss of $917,822. Research and development consumed $342,874; general and administrative costs ran $464,318. Over the first six months of 2026, cash used in operations totaled $1.46 million. That is a burn rate of roughly $240,000 per month — and management itself flagged that without additional financing, the company has working capital for only the next three months from the end of the quarter.

This isn't a company temporarily between funding rounds. It is a pre-commercial venture that has been losing money since inception and whose financial statements carry a going-concern warning — the accounting signal that there is "substantial doubt" the company can continue operating.

What the GHS agreement actually is

The agreement, signed September 8, gives NewHydrogen the option to sell common stock to GHS Investments over 24 months, up to $3 million in aggregate proceeds. It works through a "put" mechanism: NewHydrogen directs a put notice, GHS buys the shares at 92.5% of the lowest traded price over the prior 10 trading days, and then GHS resells those shares on the open market. The company gets cash; shareholders get dilution.

GHS can't accumulate more than 4.99% of outstanding shares, which limits each individual put to a small dollar amount between $10,000 and $1 million. The company must also file a Form S-1 registration statement within 30 days and pursue effectiveness within 90 days. Neither party is locked in — either can walk away with 90 days' notice.

This is not a commitment. It is an option. GHS doesn't have to buy any shares. NewHydrogen can direct puts, but if the S-1 stalls or if the trading volume can't absorb GHS's resale of shares, the money never materializes. And this is the second GHS facility in under 18 months. The original agreement, dated May 2025, was also for up to $3 million; as of April 2026, only $1.35 million had been drawn.

$3 million in context

Even if the full $3 million comes through, at a current burn rate of roughly $1 million per quarter it extends the runway by about three additional quarters. That is not a bridge to revenue — it is a bridge to the next financing round. And the dilution it creates is substantial. With roughly 820 million shares outstanding and a stock price around $0.016 per share, issuing enough shares to raise $3 million adds hundreds of millions of new shares to a float that already includes roughly 567 million outstanding options and 229 million warrants. If 35 million shares of Series C convertible preferred stock convert at $0.0014 per share, they would become roughly 2.46 billion additional shares.

The math works both ways. Every dollar raised through dilution means each existing share represents a smaller claim on a company that still has no product to sell.

The counterparty

GHS Investments has done dozens of equity financing agreements with micro-cap and penny-stock issuers. The same structure repeated across the board. In August 2024, the SEC issued a public statement highlighting GHS's trading activities involving penny stocks, noting that the firm acquires convertible notes from penny-stock issuers and converts them into stock. The statement didn't accuse GHS of wrongdoing — but it flagged the pattern for investor awareness.

For a retail investor, the question is simple: when your only source of operating capital is a structured equity facility with a counterparty the SEC has flagged for its penny-stock trading practices, how much confidence do you place in the durability of that lifeline?

What this means for an investor

NewHydrogen is building technology that could, in theory, produce hydrogen cheaper than electrolysis. The ThermoLoop process, developed with UC Santa Barbara, uses heat instead of electricity to split water. The company just filed its third patent on the technology and has announced a collaboration with NuCube Energy to explore pairing ThermoLoop with small modular nuclear reactors. None of that is wrong. It's all true. It's also none of it revenue-generating, and none of it changes the arithmetic.

The GHS agreement is not a sign of momentum. It is a lifeline. It keeps the doors open for a company that has spent $180 million and decades developing a technology that hasn't yet produced a commercial product. For an investor with a few dollars to throw at a moonshot, that may not matter. But for someone looking for cash flows, a margin of safety, or a path from price to value, there is nothing here to build on.

The question isn't whether NewHydrogen secured financing. The question is whether a company with $740,000 in cash, no revenue, and a quarterly burn approaching $1 million can bridge from laboratory to commercial pilot without consuming every share in the process. The answer, at this point, is still unknown.